RenovoRx Inc. (RNXT)
1.35
0.03 (2.27%)
At close: Jan 15, 2025, 12:37 PM
undefined% (undefined)
| Bid | 1.34 |
| Market Cap | 32.40M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.58 |
| PE Ratio (ttm) | -2.33 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 1.35 |
| Volume | 15,228 |
| Avg. Volume (20D) | 66,711 |
| Open | 1.33 |
| Previous Close | 1.32 |
| Day's Range | 1.32 - 1.36 |
| 52-Week Range | 0.77 - 1.86 |
| Beta | undefined |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California....
Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol RNXT
Website https://renovorx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for RNXT stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 381.48% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+15.97%
RenovoRx shares are trading higher after the compa...
Unlock content with
Pro Subscription
